📰 Michael Strapazon News
Michael Strapazon News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Michael Strapazon. Real-time updates on events, politics, business and more.
June 4, 2023
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global...
May 30, 2023
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new research examining the use of Otezla® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC...
May 30, 2023
MOSAIC Study is First to use MRI to Assess Inflammation in Peripheral Joints and Entheses in Psoriatic Arthritis Patients Exploratory Analysis Examines Effects of Otezla on Cardiometabolic... | June 7, 2023
April 19, 2023
Appeals Court Affirms Validity of Patent Expiring in 2028 THOUSAND OAKS, Calif., April 19, 2023 /PRNewswire/ -- Amgen today announced that the U.S. Court of Appeals for the Federal Circuit has... | June 19, 2023
April 19, 2023
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court...
March 23, 2023
How an obscure middleman system plays a key role in keeping US drug prices sky-high
January 31, 2023
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States....
January 6, 2023
/PRNewswire/ -- Amgen (NASDAQ:AMGN) and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden...
January 4, 2023
/PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 J.P. Morgan Healthcare Conference at 6:45 p.m. ET on Monday, January 9, 2023. Robert A. Bradway,...
November 7, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of investigational olpasiran (formerly AMG 890)...